Lung cancer screening trial using tumor and blood test results
Part of Cancer, Lungs & breathing clinical trials.
This trial helps sort people with previously treated lung cancer into the best next treatment options by using new tumor tissue (and sometimes blood) test results. It may help you get matched to therapies based on features like PD-L1 and other biomarkers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (any subtype) proven by a biopsy or fine-needle sample
- Your cancer is stage IV or has come back (recurrent)
- You must be able to provide enough tumor tissue for testing (at least 20% tumor cells and enough tumor volume)
- You must share your tumor sample with Foundation Medicine for biomarker tests, and agree to keep leftover tissue for future research
- You must be 18 or older and able to do daily activities fairly normally (performance status 0–1)
- You cannot have certain common gene changes (EGFR, ALK, ROS1, BRAF) unless you already tried the standard targeted treatments for them
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Hear when a new Previously Treated Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.